Falloposcope for early screening of high-grade serous ovarian carcinoma

High-grade serous carcinoma (HGSC) of the ovary is the most common and lethal subtype of ovarian cancer, representing the deadliest gynecological malignancy. Due to nonspecific symptoms and the absence of an effective screening tool for average-risk patients, most cases are diagnosed at advanced stages. As a result, fewer than 50 % of patients survive beyond five years post-diagnosis. Current screening methods, such as transvaginal ultrasound and CA-125 blood tests, are inadequate for early detection in the general as well as high-risk population. A promising innovation, the falloposcope, is being developed for routine screening, to detect ovarian cancer earlier, improve treatment outcomes, and enhancing survival rates.